Protect medication abortion access

Protect medication abortion access by securing stockpiles of medication, filing a Supreme Court amicus brief, and contingency planning in the face of anti-abortion litigation.
RFA Affirms the Safety of Mifepristone to Senate HELP Committee
  • Alliance
    •
  • Alliance
    •  January 14, 2026

    RFA Affirms the Safety of Mifepristone to Senate HELP Committee

    The Reproductive Freedom Alliance (RFA)–a nonpartisan coalition of 23 governors committed to protecting and expanding reproductive freedom–today submitted a statement for the record to the Chair and Ranking Member of the Senate Committee on Health, Education, Labor, and Pensions (HELP). The statement is in connection with the HELP Committee hearing on medication abortion on January 14 and calls on lawmakers to reject politicized, non-peer reviewed claims that contradict decades of scientific evidence.
    Reproductive Freedom Alliance Urges FDA to Uphold Science on Mifepristone
  • Alliance
    •
  • Alliance
    •  October 14, 2025

    Reproductive Freedom Alliance Urges FDA to Uphold Science on Mifepristone

    The Reproductive Freedom Alliance — a nonpartisan coalition of 23 governors committed to protecting and expanding reproductive health care — today submitted a letter to the U.S. Department of Health and Human Services (HHS) and Food and Drug Administration (FDA) urging Secretary Robert F. Kennedy Jr. and Commissioner Makary to reject political interference and stand by decades of scientific evidence supporting mifepristone’s safety and effectiveness.
    Gov. Pritzker Signs Bills to Fortify Reproductive Health Care in Illinois
  • Illinois
    •
  • Illinois
    •

    Gov. Pritzker Signs Bills to Fortify Reproductive Health Care in Illinois

    Gov. Pritzker signed an expanded state shield law (HB3637) protecting health care providers from discipline for providing health care services that are lawful in Illinois, and HB3709 which requires public colleges and universities to offer contraception and medication abortion if they have an on-campus pharmacy or student health center.
    Challenging Mifepristone Restrictions
  • Minnesota
    •
  • Minnesota
    •  August 22, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Minnesota joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Oregon
    •
  • Oregon
    •  August 22, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Oregon co-led a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Maryland
    •
  • Maryland
    •  August 21, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Maryland joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Connecticut
    •
  • Connecticut
    •  August 21, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Connecticut joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Michigan
    •
  • Michigan
    •  August 20, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Michigan joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Illinois
    •
  • Illinois
    •  August 20, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Illinois joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”
    Challenging Mifepristone Restrictions
  • Hawaiʻi
    •
  • Hawaiʻi
    •  August 20, 2025

    Challenging Mifepristone Restrictions

    In August 2025, Hawai‘i joined a multi-state coalition in filing a petition to the U.S. Food and Drug Administration to remove medically unnecessary, burdensome restrictions on mifepristone, a safe and effective abortion medication. The petition states that “given mifepristone’s well-established safety record in the United States over the last 25 years, its critical importance for abortion care and miscarriage management in Petitioner States, and the undue burdens the Mifepristone REMS Program places on patient access and the health care delivery system, the Mifepristone REMS Program should be removed in its entirety, or alternatively, FDA should exercise its discretion not to enforce the Mifepristone REMS Program (or elements thereof) in Petitioner States.”